What is OKYO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OKYO?

P/E (TTM) is n/a and 52-week range is £1.26 to £3.20 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OKYO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OKYO?

The company profile lists net income (TTM) near -$5M, EPS (TTM) near -£0.24 when available from the market-data feed. Figures are informational and may lag live markets.

Where is OKYO Pharma Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in London, GB, 21.8M shares outstanding, ISIN GG00BMFG5F62 when available from company profile and filing metadata.

OKYO Pharma Ltd

$OKYO

Health Care · Biotechnology

IR Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

OKYO Pharma Ltd

$OKYO

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Employees

4

Website

okyopharma.com/

IPO

2018-07-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

GG00BMFG5F62

Headquarters

London, GB

Shares outstanding

21.8M

NAICS sector

Manufacturing

Institutional ownership

20.12%

Browse other companiesFree AI scores and summaries for more stocks

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Employees

4

Website

okyopharma.com/

IPO

2018-07-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)